论文部分内容阅读
已知YY肽(PYY)或其同类物BIM-43004-1可抑制人体胰腺癌细胞生长,它是一种36氨基酸肠道激素,可以降低胰腺内、外分泌.BIM-43004-1是PYY-Y2受体的促效剂,能减少未经治疗胰腺癌细胞的线粒体活力.作者在动物体内观察PYY和BIM-43004-1对胰腺癌生长的作用.取48只雄性裸鼠,种植100000～150000人体胰腺癌细胞MiaPaCa-2于鼠胰腺体内.一周后,分别经微渗透泵注射PYY或BIM-43004-1200 pmol/kg·hr共 2、3或4周,各置盐水注射对照组.体外测定细胞内环一磷酸腺苷(cAMP)值和进行受体结合研究.尸解时测胰腺肿瘤大小和重量.结果 (一)体内胰腺肿瘤生长对射150000个Mia PaCa2细胞后7天均可扪及胰腺肿瘤1～2mm大小,2周后肉眼可见肿瘤,故选择注射肿瘤细胞后7天进行内分泌治疗.(二)体内胰腺肿瘤对PYY的影响在PYY治疗2、3或4周后均见胰腺肿瘤生长受限,尤以用药3周的效果最显著,其肿瘤容积和大小比对照组分别降低40%和30%.(三)治疗后动物体重的变化在用药4周后测动物的体重,
It is known that YY peptide (PYY) or its analog BIM-43004-1 inhibits the growth of pancreatic cancer cells in humans. It is a 36-amino acid intestinal hormone that reduces intra- and exocrine pancreas. BIM-43004-1 is PYY-Y2. Receptor agonists can reduce the mitochondrial viability of untreated pancreatic cancer cells. The authors observed the effect of PYY and BIM-43004-1 on the growth of pancreatic cancer in animals. 48 male nude mice were implanted and planted 100,000 to 150,000 humans. The pancreatic cancer cell MiaPaCa-2 was in vivo in the rat pancreas. After one week, they were injected with PYY or BIM-43004-1200 pmol/kg·hr by microosmotic pump for 2, 3 or 4 weeks respectively. Each saline was injected into the control group. Cells were assayed in vitro. Inner Ring Adenosine Phosphate (cAMP) Values and Receptor Binding Study. Autopsy measurements of pancreatic tumor size and weight. Results (i) In vivo pancreatic tumor growth can affect pancreas and pancreas 7 days after injection of 150,000 Mia PaCa2 cells. The size of the tumor was 1 to 2 mm. Tumors were visible to the naked eye 2 weeks later. Endocrine therapy was performed 7 days after the injection of tumor cells. (B) Effect of pancreatic tumors in vivo on PYY Pancreatic tumor growth restriction was observed after 2, 3, or 4 weeks of PYY treatment. , especially the effect of the medication for 3 weeks is the most significant, the tumor volume and size ratio of the control component Reduced by 40% and 30%. Change in animal body weight in body weight of animals measured after 4 weeks (c) the treatment,